In the life sciences industry, there is a wide variety of directions that companies can go. Many high-profile biopharma companies have a focus on messenger RNA (mRNA), and some are broadening their horizons by taking an interest in artificial intelligence. One company, Anima Biotech, has a unique approach to both.
Anima Biotech, headquartered in Bernardsville, NJ, is merging mRNA therapeutics with its own AI and bioinformatics capability. Yochi Slonim, co-founder and chief executive officer of Anima Biotech, took time to speak with BioSpace about the company and mRNA therapeutics.
Slonim started with an introduction to genetic translation, which is the process of mRNA delivering genetic code to ribosomes, and drug development. Slonim noted that traditional drug development involves small molecules. These small molecules, he said, “bind to the targets, a pocket in the protein, and disarm the protein from doing its chemical activity. When there is no lock, they are called hard targets or undruggable targets, because the industry for over 70 years has been unable to find them.”